Technical Analysis for ZYME - Zymeworks Inc.

Grade Last Price % Change Price Change
grade C 25.84 1.02% 0.26
ZYME closed up 1.02 percent on Wednesday, September 18, 2019, on 57 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Down
See historical ZYME trend table...

Date Alert Name Type % Chg
Stochastic Reached Oversold Weakness 0.00%
Oversold Stochastic Weakness 0.00%
20 DMA Resistance Bearish 1.02%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.04%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.86%
Narrow Range Bar Range Contraction 0.86%
NR7 Range Contraction 0.86%
NR7-2 Range Contraction 0.86%
Down 3 Days in a Row Weakness 0.86%
Down 4 Days in a Row Weakness 0.86%

Older signals for ZYME ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Zymeworks Inc is a Canada-based clinical-stage biopharmaceutical company. The Company focuses on the discovery, development and commercialization of multifunctional biotherapeutics. The Company's ZymeCAD platform is for protein modeling and structure-guided protein engineering. The Company's platforms include Azymetric Platform, AlbuCORE Platform, EFECT Platform and Zymelink Conjugation Platform + Cytotoxins. The Company's lead product candidate, ZW25, is a bispecific antibody, which is being evaluated in an adaptive Phase I clinical trial. Its ZW33 is a bi-specific antibody that delivers a cytotoxic payload to cancers cells by binding to different epitopes (bi-paratopic targeting) of the overexpressed HER2 protein. It focuses on developing a pipeline of preclinical product candidates and discovery-stage programs in immuno-oncology and other therapeutic areas. It analyzes protein characteristics to develop the scope of protein engineering to tackle biological systems.
Medicine Biopharmaceutical Medical Specialties Immunology Cancers Immune System Monoclonal Antibodies Cancer Immunotherapy Antibody Sutro Biopharma Glycoproteins Biological Systems Protein Engineering
Is ZYME a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.75
52 Week Low 10.72
Average Volume 243,756
200-Day Moving Average 18.7729
50-Day Moving Average 24.9968
20-Day Moving Average 26.284
10-Day Moving Average 26.864
Average True Range 1.3741
ADX 25.96
+DI 22.6032
-DI 18.5802
Chandelier Exit (Long, 3 ATRs ) 25.6277
Chandelier Exit (Short, 3 ATRs ) 28.1123
Upper Bollinger Band 28.7227
Lower Bollinger Band 23.8453
Percent B (%b) 0.41
BandWidth 18.556536
MACD Line 0.3642
MACD Signal Line 0.6342
MACD Histogram -0.27
Fundamentals Value
Market Cap 654.77 Million
Num Shares 25.3 Million
EPS -3.52
Price-to-Earnings (P/E) Ratio -7.34
Price-to-Sales 35.32
Price-to-Book 2.18
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 27.19
Resistance 3 (R3) 27.06 26.48 26.97
Resistance 2 (R2) 26.48 26.14 26.55 26.89
Resistance 1 (R1) 26.16 25.92 26.32 26.29 26.81
Pivot Point 25.58 25.58 25.66 25.65 25.58
Support 1 (S1) 25.26 25.24 25.42 25.39 24.87
Support 2 (S2) 24.68 25.02 24.75 24.79
Support 3 (S3) 24.36 24.68 24.72
Support 4 (S4) 24.49